4.4 Review

Differential molecular mechanistic behavior of HDACs in cancer progression

期刊

MEDICAL ONCOLOGY
卷 39, 期 11, 页码 -

出版社

HUMANA PRESS INC
DOI: 10.1007/s12032-022-01770-4

关键词

Cancer; Histone deacetylases; Metastasis; Stemness potential; Angiogenesis; Metabolism

类别

资金

  1. Council of Scientific and Industrial Research (CSIR), New Delhi
  2. DST FIST [SR/FST/LS-I/2017/49]
  3. Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda

向作者/读者索取更多资源

Genetic aberration and epigenetic modifications play important roles in cancer development. HDACs, a type of histone modifier, regulate various aspects of cell survival, apoptosis, and metastasis, and are considered potential targets for anti-cancer drug development.
Genetic aberration including mutation in oncogenes and tumor suppressor genes transforms normal cells into tumor cells. Epigenetic modifications work concertedly with genetic factors in controlling cancer development. Histone acetyltransferases (HATs), histone deacetylases (HDACs), DNA methyltransferases (DNMTs) and chromatin structure modifier are prospective epigenetic regulators. Specifically, HDACs are histone modifiers regulating the expression of genes implicated in cell survival, growth, apoptosis, and metabolism. The majority of HDACs are highly upregulated in cancer, whereas some have a varied function and expression in cancer progression. Distinct HDACs have a positive and negative role in controlling cancer progression. HDACs are also significantly involved in tumor cells acquiring metastatic and angiogenic potential in order to withstand the anti-tumor microenvironment. HDACs' role in modulating metabolic genes has also been associated with tumor development and survival. This review highlights and discusses the molecular mechanisms of HDACs by which they regulate cell survival, apoptosis, metastasis, invasion, stemness potential, angiogenesis, and epithelial to mesenchymal transitions (EMT) in tumor cells. HDACs are the potential target for anti-cancer drug development and various inhibitors have been developed and FDA approved for a variety of cancers. The primary HDAC inhibitors with proven anti-cancer efficacy have also been highlighted in this review.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据